Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

NeoStem Licenses Stem Cell Wound Healing Product

publication date: May 5, 2009

NeoStem, Inc. in-licensed worldwide rights to Primcel, a mesenchymal (bone marrow) stem cell product that, in early clinical studies, shows promise of accelerating the healing of chronic wounds. NeoStem has opened adult stem cell collection sites in the US and has invested in regenerative medicine companies in China. When NeoStem received new capital from Asian investors in April 2009, the company declared its intention to enter the medical tourism business. More details...

Stock Symbol: (NYSE Amex: NBS)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital